keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/29779412/primary-gastric-lymphoma-epidemiology-clinical-diagnosis-and-treatment
#1
Luis Miguel Juárez-Salcedo, Lubomir Sokol, Julio C Chavez, Samir Dalia
Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma to aggressive diffuse large B-cell lymphoma. The PGL is a relatively rare cancer and easily misdiagnosed due to its unspecific symptoms of the digestive tract. The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of PGL...
January 2018: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/29774105/pre-clinical-activity-of-targeting-the-pi3k-akt-mtor-pathway-in-burkitt-lymphoma
#2
Maria Bhatti, Thomas Ippolito, Cory Mavis, Juan Gu, Mitchell S Cairo, Megan S Lim, Francisco Hernandez-Ilizaliturri, Matthew J Barth
Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been implicated in Burkitt lymphomagenesis and increased PI3K/AKT activation has been associated with worse outcomes in adults with aggressive B-cell non-Hodgkin lymphoma (B-NHL). Inhibitors of the PI3K/AKT pathway have been approved for the treatment of refractory indolent B-NHL and continue to be investigated for treatment of aggressive B-NHLs...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29769262/a-new-molecular-assay-and-genomic-complexity-predict-outcome-in-conventional-and-leukemic-non-nodal-mantle-cell-lymphoma
#3
Guillem Clot, Pedro Jares, Eva Giné, Alba Navarro, Cristina Royo, Magda Pinyol, David Martín-Garcia, Santiago Demajo, Blanca Espinet, Antonio Salar, Ana Ferrer, Ana Muntañola, Marta Aymerich, Hilka Rauert-Wunderlich, Elaine S Jaffe, Joseph M Connors, Randy D Gascoyne, Jan Delabie, Armando López-Guillermo, German Ott, George W Wright, Louis M Staudt, Andreas Rosenwald, David W Scott, Lisa M Rimsza, Sílvia Beà, Elías Campo
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic non-nodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. Herein, we describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29758320/neoadjuvant-crizotinib-in-alk-rearranged-inflammatory-myofibroblastic-tumor-of-the-urinary-bladder-a-case-report
#4
Yoshiyuki Nagumo, Aiko Maejima, Yuta Toyoshima, Motokiyo Komiyama, Kan Yonemori, Akihiko Yoshida, Hiroyuki Fujimoto
INTRODUCTION: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor that involves various organs, but has a predilection for the urinary bladder in the genitourinary tract. Given that approximately half of all IMT cases have anaplastic lymphoma kinase (ALK) rearrangements, the ALK inhibitor crizotinib is suggested as a promising treatment for unresectable cases. No reports on neoadjuvant crizotinib therapy for locally advanced IMT of the bladder are available. PRESENTATION OF CASE: We report a case of a 17-year-old Japanese boy referred to our institution for painful urination and increased urinary frequency...
May 1, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29754401/treatment-of-localized-stage-follicular-lymphoma
#5
REVIEW
Marc Sorigue, Victòria Tuset, Juan-Manuel Sancho
Follicular lymphoma (FL) is the most common indolent lymphoma and it most frequently presents in an advanced-stage. Therapeutic considerations for advanced-stage are different from those of localized-stage FL, in which radiotherapy (RT) is generally recommended. However, the available evidence suffers from shortcomings that are relatively specific to this clinical entity due to its rarity and long survival with all available treatment modalities, including that most of the existing evidence originated at a time when diagnostic classifications, staging procedures and radiotherapeutic standards were different from those available today and when anti-CD20 monoclonal antibodies were not available...
May 12, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29743350/high-throughput-sequencing-of-the-t-cell-receptor-%C3%AE-gene-identifies-aggressive-early-stage-mycosis-fungoides
#6
Adele de Masson, John T O'Malley, Christopher P Elco, Sarah S Garcia, Sherrie J Divito, Elizabeth L Lowry, Marianne Tawa, David C Fisher, Phillip M Devlin, Jessica E Teague, Nicole R Leboeuf, Ilan R Kirsch, Harlan Robins, Rachael A Clark, Thomas S Kupper
Mycosis fungoides (MF), the most common cutaneous T cell lymphoma (CTCL) is a malignancy of skin-tropic memory T cells. Most MF cases present as early stage (stage I A/B, limited to the skin), and these patients typically have a chronic, indolent clinical course. However, a small subset of early-stage cases develop progressive and fatal disease. Because outcomes can be so different, early identification of this high-risk population is an urgent unmet clinical need. We evaluated the use of next-generation high-throughput DNA sequencing of the T cell receptor β gene ( TCRB ) in lesional skin biopsies to predict progression and survival in a discovery cohort of 208 patients with CTCL (177 with MF) from a 15-year longitudinal observational clinical study...
May 9, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29741263/the-2017-who-update-on-mature-t-and-natural-killer-nk-cell-neoplasms
#7
REVIEW
E Matutes
Over the last decade, there has been a significant body of information regarding the biology of the lymphoid neoplasms. This clearly supports the need for updating the 2008 WHO (World Health Organization) classification of haematopoietic and lymphoid tumours. The 2017 WHO classification is not a new edition but an update and revision of the 4th edition. New provisional entities but not new definitive entities are included, and novel molecular data in most of the entities and changes in the nomenclature in few of them have been incorporated...
May 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29741105/systematic-literature-review-of-health-related-quality-of-life-among-aggressive-non-hodgkin-lymphoma-survivors
#8
Vincent W Lin, Barbara Blaylock, Josh Epstein, Anna Purdum
OBJECTIVE: Literature have shown that a proportion of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard chemotherapy will have long-term life expectancy comparable to those in the age-adjusted general population (Maurer et al. 2014). This systematic literature review summarizes current literature regarding health-related quality of life (HRQoL) of long-term (≥2 years) survivors of aggressive NHL. METHODS: Electronic databases (without restriction on years) and abstracts from four major oncology and HRQoL conferences from 2014-2017 were searched...
May 9, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29740389/a-rare-case-of-composite-dural-extranodal-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#9
REVIEW
Mark Bustoros, Benjamin Liechty, David Zagzag, Cynthia Liu, Timothy Shepherd, Deborah Gruber, Bruce Raphael, Dimitris G Placantonakis
Background: Primary extranodal marginal zone lymphoma (MZL) of the dura is a rare neoplastic entity in the central nervous system (CNS). Methods: We used literature searches to identify previously reported cases of primary dural MZL. We also reviewed clinical, pathologic, and radiographic data of an adult patient with concurrent dural MZL and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Results: We identified 104 cases of dural MZL in the literature...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29738333/sox11-a-key-oncogenic-factor-in-mantle-cell-lymphoma
#10
Renée Beekman, Virginia Amador, Elias Campo
PURPOSE OF REVIEW: SOX11 has emerged as a key transcription factor in the pathogenesis of mantle cell lymphoma (MCL) whereas it is not expressed in normal B cells or virtually in any other mature B-cell neoplasm. This review will examine the role of SOX11 as a biomarker in MCL, the new information on its transcriptional targets, and the mechanisms regulating its expression in MCL. RECENT FINDINGS: SOX11 is highly expressed in conventional MCL, including cyclin D1-negative cases, but it is not expressed in the indolent leukemic nonnodal MCL subtype...
May 5, 2018: Current Opinion in Hematology
https://www.readbyqxmd.com/read/29735434/-primary-uveal-lymphoma-effectively-treated-with-radiotherapy-a-case-report-and-literature-review
#11
Ruo-Xin Wu, Tao Yang, Zhu-Ping Xu
Primary uveal lymphoma is a type of intra-ocular lymphoma. Unlike the intra-ocular lymphomas involving the retina and vitreous, primary uveal lymphoma generally has a low-grade nature and an indolent clinical course. It is a relatively rare condition, and the diagnosis can be challenging. We present a rare case of primary uveal lymphoma involving the choroid, ciliary body, iris and conjunctiva that was successfully treated with radiotherapy and achieved full remission.
April 20, 2018: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/29731969/indolent-lymphoma-with-composite-histology-and-simultaneous-transformation-at-initial-diagnosis-exhibit-clinical-features-similar-to-de-novo-diffuse-large-b-cell-lymphoma
#12
Hanno Witte, Harald Biersack, Svenja Kopelke, Dirk Rades, Hartmut Merz, Veronica Bernard, Hendrik Lehnert, Niklas Gebauer
While various studies characterized clinical and prognostic properties of de novo diffuse large B-Cell lymphoma (DLBCL) and transformed indolent lymphomas, the clinicopathological features of indolent lymphoma and simultaneous secondary transformation upon initial diagnosis (ssDLBCL) are insufficiently established. Between 2010 and 2017, 247 consecutive patients admitted to our institution and treated for DLBCL were investigated for composite histology of ssDLBCL-type. Upon systematical histopathological evaluation composite histology was identified in 22/247 cases (8...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29729707/swainsonine-induces-apoptosis-of-rat-cardiomyocytes-via-mitochondria%C3%A2-mediated-pathway
#13
Xiang Zheng, Shushu Wang, Dakai Chen, Xiaoming Yang
Swainsonine is an Astragalus membranaceus extract. It is indole, alkaloid, and soluble in water. Its effect on rat cardiomyocytes apoptosis, and the mechanisms underlying that effect, were investigated by inducing apoptosis in H9c2 cells. This was detected by MTT assay, Annexin V-FITC/propidium iodide double staining and western blotting. Flow cytometry and fluorescence microscopy were used to confirm swainsonine's effect on mitochondrial membrane potential and levels of reactive oxygen species, while an ATP-dependent bioluminescence assay kit served to find the ATP contents...
April 30, 2018: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/29725472/volatile-metabonomic-profiling-in-urine-to-detect-novel-biomarkers-for-b-cell-non-hodgkin-s-lymphoma
#14
Qingling Hua, Lin Wang, Chan Liu, Lingling Han, Yazhong Zhang, Hu Liu
To date, there have been a limited number of useful biomarkers for the screening and monitoring of B-cell non-Hodgkin's lymphoma (B-NHL), which leads to the impetus to discover novel biomarkers for the disease. In the present study, gas chromatography-mass spectrometry (GC-MS) combined with head-space solid-phase micro-extraction (HS-SPME) was employed to analyze the volatile metabolites in the urine samples of 131 subjects. The subjects were divided into 4 main groups: Aggressive B-NHL, indolent B-NHL, benign lymphatic diseases patients and healthy volunteers...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29719928/long-term-follow-up-of-2-patients-treated-with-90-y-rituximab-radioimmunotherapy-for-relapse-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#15
S Golstein, K Muylle, M Vercruyssen, C Spilleboudt, A de Wind, D Bron
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma (< 5% of Hodgkin's lymphomas) predominantly affecting the middle-aged man, with an indolent behavior. Given the rare occurrence of this lymphoma, there are currently no clear guidelines for initial treatment or relapse. In this report, we present the follow up of two patients treated by radioimmunotherapy for first relapse of their NLPHL. Both patients were initially treated with rituximab and relapsed 1 year after the end of their treatment...
May 2, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29719020/primary-cutaneous-b-cell-lymphomas-clinical-and-histopathologic-features-differential-diagnosis-and-treatment
#16
Steven T Chen, Jeffrey Barnes, Lyn Duncan
Cutaneous B-cell lymphomas (CBCLs) are a heterogeneous group of diseases that can have variable presentations, prognoses, and treatments. The proper identification of a CBCL hinges on proper histopathologic and clinical evaluation. Comprising 25% to 30% of the primary cutaneous lymphomas, incident cases of CBCL are rare. Given the variable natural history of the CBCL, proper classification is critical so that patients are treated appropriately. CBCLs can be divided into 2 main groups: indolent and aggressive...
March 2018: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29719019/primary-cutaneous-cd4-small-medium-t-cell-lymphoproliferative-disorder-clinical-and-histopathologic-features-differential-diagnosis-and-treatment
#17
Alejandro A Gru, Mark R Wick, Mary Eid
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder usually presents as a slow-growing and asymptomatic solitary lesion in the form of a nodule or tumor in the head and neck region. By definition, it is histologically characterized by small- to medium-sized CD4+ lymphocytes involving the dermis in a dense and either nodular or diffuse pattern. Epidermotropism should be absent or minimal. Tumor cells are accompanied by numerous reactive B cells, plasma cells, histiocytes, and eosinophils...
March 2018: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29712895/waldenstr%C3%A3-m-macroglobulinemia-treatment-algorithm-2018
#18
REVIEW
Morie A Gertz
Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma...
May 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29707540/lymphoma-and-lymphomagenesis-in-primary-sj%C3%A3-gren-s-syndrome
#19
REVIEW
Alessia Alunno, Maria Comasia Leone, Roberto Giacomelli, Roberto Gerli, Francesco Carubbi
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease mainly affecting exocrine glands and leading to impaired secretory function. The clinical picture is dominated by signs and symptoms of mucosal dryness and the course of the disease is mild and indolent in the majority of cases. However, a subgroup of patients can also experience extraglandular manifestations that worsen the disease prognosis. pSS patients are consistently found to have a higher risk of developing non-Hodgkin lymphoma (NHL) compared with patients with other autimmune disorders and to the general population...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29702521/dna-damage-pathways-and-b-cell-lymphomagenesis
#20
Gero Knittel, Tim Rehkämper, Pascal Nieper, Anna Schmitt, Ruth Flümann, H Christian Reinhardt
PURPOSE OF REVIEW: Recent lymphoma genome sequencing projects have shed light on the genomic landscape of indolent and aggressive lymphomas, as well as some of the molecular mechanisms underlying recurrent mutations and translocations in these entities. Here, we review these recent genomic discoveries, focusing on acquired DNA repair defects in lymphoma. In addition, we highlight recently identified actionable molecular vulnerabilities associated with recurrent mutations in chronic lymphocytic leukemia (CLL), which serves as a model entity...
April 26, 2018: Current Opinion in Hematology
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"